Cargando…
Nutraceuticals: opening the debate for a regulatory framework
Currently, nutraceuticals do not have a specific definition distinct from those of other food‐derived categories, such as food supplements, herbal products, pre‐ and probiotics, functional foods, and fortified foods. Many studies have led to an understanding of the potential mechanisms of action of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867125/ https://www.ncbi.nlm.nih.gov/pubmed/29433155 http://dx.doi.org/10.1111/bcp.13496 |
_version_ | 1783308930309423104 |
---|---|
author | Santini, Antonello Cammarata, Silvia Miriam Capone, Giacomo Ianaro, Angela Tenore, Gian Carlo Pani, Luca Novellino, Ettore |
author_facet | Santini, Antonello Cammarata, Silvia Miriam Capone, Giacomo Ianaro, Angela Tenore, Gian Carlo Pani, Luca Novellino, Ettore |
author_sort | Santini, Antonello |
collection | PubMed |
description | Currently, nutraceuticals do not have a specific definition distinct from those of other food‐derived categories, such as food supplements, herbal products, pre‐ and probiotics, functional foods, and fortified foods. Many studies have led to an understanding of the potential mechanisms of action of pharmaceutically active components contained in food that may improve health and reduce the risk of pathological conditions while enhancing overall well‐being. Nevertheless, there is a lack of clear information and, often, the claimed health benefits may not be properly substantiated by safety and efficacy information or in vitro and in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed. An officially shared and accepted definition of nutraceuticals is still missing, as nutraceuticals are mostly referred to as pharma‐foods, a powerful toolbox to be used beyond the diet but before the drugs to prevent and treat pathological conditions, such as in subjects who may not yet be eligible for conventional pharmaceutical therapy. Hence, it is of utmost importance to have a proper and unequivocal definition of nutraceuticals and shared regulations. It also seems wise to assess the safety, mechanism of action and efficacy of nutraceuticals with clinical data. A growing demand exists for nutraceuticals, which seem to reside in the grey area between pharmaceuticals and food. Nonetheless, given specific legislation from different countries, nutraceuticals are experiencing challenges with safety and health claim substantiation. |
format | Online Article Text |
id | pubmed-5867125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58671252018-03-29 Nutraceuticals: opening the debate for a regulatory framework Santini, Antonello Cammarata, Silvia Miriam Capone, Giacomo Ianaro, Angela Tenore, Gian Carlo Pani, Luca Novellino, Ettore Br J Clin Pharmacol Reviews Currently, nutraceuticals do not have a specific definition distinct from those of other food‐derived categories, such as food supplements, herbal products, pre‐ and probiotics, functional foods, and fortified foods. Many studies have led to an understanding of the potential mechanisms of action of pharmaceutically active components contained in food that may improve health and reduce the risk of pathological conditions while enhancing overall well‐being. Nevertheless, there is a lack of clear information and, often, the claimed health benefits may not be properly substantiated by safety and efficacy information or in vitro and in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed. An officially shared and accepted definition of nutraceuticals is still missing, as nutraceuticals are mostly referred to as pharma‐foods, a powerful toolbox to be used beyond the diet but before the drugs to prevent and treat pathological conditions, such as in subjects who may not yet be eligible for conventional pharmaceutical therapy. Hence, it is of utmost importance to have a proper and unequivocal definition of nutraceuticals and shared regulations. It also seems wise to assess the safety, mechanism of action and efficacy of nutraceuticals with clinical data. A growing demand exists for nutraceuticals, which seem to reside in the grey area between pharmaceuticals and food. Nonetheless, given specific legislation from different countries, nutraceuticals are experiencing challenges with safety and health claim substantiation. John Wiley and Sons Inc. 2018-02-14 2018-04 /pmc/articles/PMC5867125/ /pubmed/29433155 http://dx.doi.org/10.1111/bcp.13496 Text en © 2018 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Santini, Antonello Cammarata, Silvia Miriam Capone, Giacomo Ianaro, Angela Tenore, Gian Carlo Pani, Luca Novellino, Ettore Nutraceuticals: opening the debate for a regulatory framework |
title | Nutraceuticals: opening the debate for a regulatory framework |
title_full | Nutraceuticals: opening the debate for a regulatory framework |
title_fullStr | Nutraceuticals: opening the debate for a regulatory framework |
title_full_unstemmed | Nutraceuticals: opening the debate for a regulatory framework |
title_short | Nutraceuticals: opening the debate for a regulatory framework |
title_sort | nutraceuticals: opening the debate for a regulatory framework |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867125/ https://www.ncbi.nlm.nih.gov/pubmed/29433155 http://dx.doi.org/10.1111/bcp.13496 |
work_keys_str_mv | AT santiniantonello nutraceuticalsopeningthedebateforaregulatoryframework AT cammaratasilviamiriam nutraceuticalsopeningthedebateforaregulatoryframework AT caponegiacomo nutraceuticalsopeningthedebateforaregulatoryframework AT ianaroangela nutraceuticalsopeningthedebateforaregulatoryframework AT tenoregiancarlo nutraceuticalsopeningthedebateforaregulatoryframework AT paniluca nutraceuticalsopeningthedebateforaregulatoryframework AT novellinoettore nutraceuticalsopeningthedebateforaregulatoryframework |